Decision to award sole supply of venlafaxine


12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride to Mylan for its Enlafax XR brand from 1 June 2017 in DHB hospitals and from 1 September 2017 in the community.

Venlafaxine hydrochloride is indicated for the treatment of major depression, generalised anxiety disorder; social anxiety disorder and panic disorder.

This decision was made following a request for tender for the supply of venlafaxine hydrochloride issued on 15 June 2016 and a consultation letter dated 10 August 2016, amended 18 August 2016.

The decision is as consulted on, except that a Brand Switch Fee will be available to pharmacies, the implementation of the stat dispensing rule will be delayed until 1 December 2017 and the reference price subsidy of the incumbent 37.5 mg strengths will be $2.13 per pack of 28 not $2.12.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , New Zealand , Tender